文献速递皮肤肿瘤

黑色素瘤的免疫检查点抑制与靶向治疗:一项以患者为导向的横断面比较多中心研究

Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-12-07

该研究在德国13个皮肤癌中心于2020年8月至2021年3月开展横断面比较研究,纳入414例接受全身治疗的黑色素瘤患者,其中359例(87%)接受免疫检查点抑制(ICI),55例(13%)接受靶向治疗(TT)。辅助治疗亚组中,TT患者报告治疗相关生活质量显著下降(p=0.02)、不良事件报告率是ICI患者的1.9倍(p=0.01)。患者总体评价积极,辅助治疗中ICI在生活质量和患者报告不良事件方面可能优于TT。

要点

  • 辅助治疗亚组中,TT患者治疗相关生活质量较ICI患者显著下降(p=0.02)。
  • 辅助治疗亚组中,TT患者报告不良事件的可能性是ICI患者的1.9倍(p=0.01)。
  • 63岁以上患者对多种患者报告结局的评价优于年轻患者。

核心结论

  • 患者对其治疗主要持积极评价。
  • 在辅助治疗中,就生活质量和患者报告的不良事件而言,ICI可能优于TT。
  • 老年黑色素瘤患者似乎受疾病影响较小,且对治疗更满意。

研究设计与样本

  • 德国全国性横断面比较研究,于2020年8月至2021年3月在13个专业皮肤癌中心开展。
  • 共纳入414例接受全身黑色素瘤治疗的患者,其中359例(87%)接受ICI,55例(13%)接受TT。
  • 约1/3患者接受辅助治疗,其余因不可切除/转移性黑色素瘤接受治疗。

主要发现

  • 仅在辅助治疗亚组中,TT患者报告治疗相关生活质量较ICI患者显著下降(p=0.02)。
  • TT患者报告不良事件的可能性是ICI患者的1.9倍,该差异仅在辅助治疗亚组中显著(p=0.01)。
  • ICI治疗间隔在辅助治疗与不可切除/转移性治疗之间差异显著(p=0.04),但所有患者无论使用何种ICI药物均认为治疗频率适当。
  • 接受达拉非尼/曲美替尼(n=37)或恩考芬尼/比美替尼(n=15)的TT患者在日常服药负担方面无差异。
  • 63岁以上患者对多种患者报告结局的评价优于年轻患者。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Choosing the adequate systemic treatment for melanoma is driven by clinical parameters and personal preferences. OBJECTIVE: Evaluation of the impact of disease and treatment on the daily life of patients receiving systemic therapy for melanoma. METHODS: A German-wide, cross-sectional comparative study was conducted at 13 specialized skin cancer centres from 08/2020 to 03/2021. A questionnaire was distributed to assess patients' perception of disease and symptoms, the impact of their current treatment on quality of life (QOL) and activities, adverse events (AEs), therapeutic visits, as well as believe in and satisfaction with their current systemic melanoma treatment. Patient-reported outcomes (PROs) were rated on a continuous numerical rating scale or selected from a given list. RESULTS: Four hundred and fourteen patients with systemic melanoma therapy were included. 359 (87%) received immune checkpoint inhibition (ICI) and 55 (13%) targeted therapy (TT). About 1/3 of patients were adjuvantly treated, the remaining because of unresectable/metastatic melanoma. In subgroup analyses, only in the adjuvant setting, TT patients reported a significant decrease in their treatment associated QOL compared to patients with ICI (p = 0.02). Patients with TT were 1.9 times more likely to report AEs than patients with ICI, a difference being significant just for the adjuvant setting (p = 0.01). ICI treatment intervals differed significantly between adjuvant and unresectable/metastatic setting (p = 0.04), though all patients, regardless of their specific ICI drug, evaluated their treatment frequency as adequate. TT patients with dabrafenib/trametinib (n = 37) or encorafenib/binimetinib (n = 15) did not differ regarding the strain of daily pill intake. Patients older than 63 years rated various PROs better than younger patients. CONCLUSIONS: Patients evaluated their treatment mainly positively. ICI might be preferred over TT regarding QOL and patient-reported AEs in the adjuvant setting. Older melanoma patients appeared to be less impacted by their disease and more satisfied with their treatment.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Thiem A, Mashhadiakbar P, Cussigh C, et al. Immune checkpoint inhibition and targeted therapy for melanoma: A patient-oriented cross-sectional comparative multicentre study. J Eur Acad Dermatol Venereol. 2022. PMID: 36433671. doi:10.1111/jdv.18778

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。